Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA1 | P02708 | 1/20 | 0.30 |
| ▸ | CHRNG | P07510 | 1/20 | 0.30 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.30 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
| ▸ | CHRND | Q07001 | 1/20 | 0.30 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.30 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL967770 | 1.00 | CHRNA1 (0.30) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 | |
| SCHEMBL968872 | 0.89 | BACE1 (0.33) | — | |
| SCHEMBL949523 | 0.86 | BACE1 (0.31) | — | |
| SCHEMBL968820 | 0.80 | BACE1 (0.55) | — | |
| SCHEMBL968863 | 0.78 | ALDH1A1 (0.34) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 | |
| SCHEMBL968545 | 0.78 | ALDH1A1 (0.34) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 | |
| SCHEMBL12851639 | 0.78 | CHRNA1 (0.34) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 | |
| SCHEMBL12851557 | 0.78 | CHRNA1 (0.34) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 | |
| SCHEMBL2119398 | 0.78 | BACE1 (0.31) | — | |
| SCHEMBL2108284 | 0.78 | BACE1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009395-A1 | BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009395-A1 | BACE INHIBITORS | BACE1, BACE2, APP | CHRNA1 2741/4885CHRNG 3262/4885CHRNB1 1340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.